New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease
Go back to New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer's disease| BARNES GROUP, Inc. (NYSE: B) | Delayed: 42.60 -1.08 (2.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $43.68 | 52 Week High | $44.27 | |||
| Open | $42.47 | 52 Week Low | $30.07 | |||
| Day High | $42.83 | P/E | 32.52 | |||
| Day Low | $41.88 | EPS | $1.31 | |||
| Volume | 4,697,969 | |||||
| BIOAMBER, Inc. (NASDAQ: BIOA) | Delayed: 8.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.49 | 52 Week High | $8.73 | |||
| Open | $8.52 | 52 Week Low | $2.86 | |||
| Day High | $8.64 | P/E | N/A | |||
| Day Low | $8.39 | EPS | $-3.82 | |||
| Volume | 229,706 | |||||
